Results 171 to 180 of about 28,689 (318)

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

, 2013
Francisco Cervantes, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali, Andres Sirulnik, Viktoriya Stalbovskaya, Mari McQuitty, Deborah Hunter, Richard S. Levy, Francesco Passamonti, Tiziano Barbui, Giovanni Barosi, Claire Harrison, Laurent Knoops, Heinz Gisslinger   +14 more
openalex   +1 more source

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis [PDF]

, 2017
Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano, Timothy Devos, Miklós Egyed, Andrzei Hellmann, Donal P. McLornan, Kazuya Shimoda, Elliott F. Winton, Wei Deng, Ronald L. Dubowy, Julia D. Maltzman, Francisco Cervantes, Jason Gotlib   +13 more
openalex   +1 more source

The Impact of Vitiligo on Patients' Quality of Life: Retrospective Observational Study

International Journal of Dermatology, EarlyView.
Vincenzo Picone, Luigi Coronella, M. Turco, Marianna Cimmino, Cataldo Patruno, Massimiliano Scalvenzi, Maddalena Napolitano   +6 more
wiley   +1 more source

Discovery of Natural Compound α‐Hederin via Large‐Scale Screening as a Targeted JAK/STAT3 Inhibitor for Ovarian Cancer Therapy

Advanced Science, Volume 12, Issue 38, October 13, 2025.
This study identifies α‐Hederin as a potent dual JAK1/JAK2 inhibitor that blocks STAT3 activation in ovarian cancer. By disrupting STAT3‐driven transcriptional programs, α‐Hederin suppresses tumor proliferation, invasion, and EMT, while enhancing cisplatin efficacy and overcoming chemoresistance.
Jiayu Wang, Pengzhan He, Cheng Liu, Xin Chen, Yilin Tan, Rui Qu, Yan Zhang, Zhou Li, Tailang Yin, Zhinang Yin   +9 more
wiley   +1 more source

Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience [PDF]

, 2017
Jessica Slostad, Patrick Hoversten, Candace L. Haddox, Kamila I. Cisak, Jonas Paludo, Ayalew Tefferi   +5 more
openalex   +1 more source

Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study

International Journal of Dermatology, EarlyView.
Mattia Cristallo, Ippolita Zaza, Michelina Francesca Daddato, Loredana Muolo, Francesco Pugliese, Alice D'Amico, Marco Casciaro, Sebastiano Gangemi, Eustachio Nettis   +8 more
wiley   +1 more source

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations [PDF]

, 2016
Barbui, T, Barosi, G, Birgegård, G, Cervantes, F, Griesshammer, M, Harrison, C., Hehlmann, R, Kiladjian, J-J, Kröger, N, Marchetti, M, McMullin, M F, Passamonti, F, Vannucchi, A   +12 more
core   +1 more source

From Genome to Geroscience: How DNA Damage Shapes Systemic Decline

BioEssays, Volume 47, Issue 10, October 2025.
Persistent DNA damage triggers systemic secretory responses including damage‐associated molecular patterns (DAMPs), the senescence‐associated secretory phenotype (SASP), and extracellular vesicles (EVs). This non‐cell‐autonomous signaling disrupts intercellular communication, driving organism‐wide dysfunction and aging, and offering new therapeutic ...
Athanasios Siametis, George A. Garinis
wiley   +1 more source

Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient [PDF]

, 2017
Yuval Ramot, Abraham Zlotogorski
openalex   +1 more source

CALR Type 1‐Like Mutations Increase Endoplasmic Reticulum Free Ca2+ and Induce ERK1/2 Activation Independent of Thrombopoietin Receptor Activation

Cell Biology International, Volume 49, Issue 10, Page 1262-1273, October 2025.
ABSTRACT Calreticulin is a multifunctional protein found in the endoplasmic reticulum lumen that is important for calcium homeostasis and glycoprotein folding. Mutations in exon 9 of the CALR gene are the second most common genetic cause of myeloproliferative neoplasms.
Mifra Faiz, Caitlin Dunstan‐Harrison, Elizabeth C. Ledgerwood   +2 more
wiley   +1 more source